PON1 and lung carcinoma: Eom et al. reported that PON1 rs662 TT/CT carriers had the lower urinary 8-hydroxydeoxyguanosine and thiobarbituric acid reactive substances levels compared with rs662 CC carriers in lung cancer patients and decreased the risk of lung cancer [34].